Appendix 6—table 3. Results from models for hospitalization endpoint.
| Single models | Global model | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Children OR (95% CI) |
Adults OR (95% CI) |
Poverall | Pinteraction | Children OR (95% CI) |
Adults OR (95% CI) |
Poverall | Pinteraction | ||
| VCAM-1 (ng/ml) | <0.001 | 0.009 | 0.092 | 0.137 | |||||
| - 1636 vs 818 | 1.28 (1.11–1.49) | 1.28 (1.03–1.60) | 1.16 (0.90–1.48) | 1.28 (0.87–1.90) | |||||
| - 3272 vs 1636 | 1.42 (1.14–1.76) | 1.46 (1.08–1.97) | 1.16 (0.81–1.64) | 1.41 (0.84–2.37) | |||||
| SDC-1 (pg/ml) | <0.001 | 0.187 | 0.006 | 0.406 | |||||
| - 2519 vs 1260 | 1.82 (1.01–3.28) | 0.79 (0.31–2.05) | 1.70 (0.84–3.41) | 0.62 (0.16–2.49) | |||||
| - 5039 vs 2519 | 2.22 (1.36–3.63) | 1.81 (0.65–5.07) | 3.70 (1.90–7.22) | 1.66 (0.39–7.07) | |||||
| Ang-2 (pg/ml) | 0.012 | 0.337 | 0.497 | 0.789 | |||||
| - 1204 vs 602 | 1.27 (1.07–1.52) | 1.21 (0.91–1.62) | 1.27 (0.92–1.77) | 1.16 (0.76–1.77) | |||||
| - 2409 vs 1204 | 1.58 (1.08–2.32) | 1.61 (0.86–3.04) | 1.63 (0.90–2.93) | 1.45 (0.70–3.01) | |||||
| IL-8 (pg/ml) | 0.007 | 0.002 | 0.024 | 0.021 | |||||
| - 14 vs 7 | 1.14 (0.90–1.44) | 0.73 (0.47–1.15) | 0.94 (0.66–1.33) | 0.63 (0.36–1.13) | |||||
| - 28 vs 14 | 0.98 (0.81–1.18) | 1.32 (0.85–2.05) | 0.70 (0.50–0.97) | 1.59 (0.81–3.12) | |||||
| IP-10 (pg/ml) | 0.002 | 0.242 | 0.005 | 0.212 | |||||
| - 3093 vs 1546 | 1.32 (1.13–1.54) | 1.10 (0.86–1.40) | 0.80 (0.56–1.14) | 0.77 (0.45–1.30) | |||||
| - 6186 vs 3093 | 1.50 (1.18–1.90) | 1.17 (0.81–1.70) | 0.84 (0.51–1.40) | 0.66 (0.32–1.35) | |||||
| IL-1RA (pg/ml) | <0.001 | 0.685 | <0.001 | 0.389 | |||||
| - 6434 vs 3217 | 1.31 (1.17–1.46) | 1.13 (0.94–1.36) | 2.05 (1.57–2.66) | 1.18 (0.73–1.89) | |||||
| - 12868 vs 6434 | 1.41 (1.11–1.80) | 1.17 (0.79–1.72) | 2.25 (1.39–3.64) | 1.19 (0.62–2.28) | |||||
| sCD163 (ng/ml) | 0.208 | 0.722 | 0.007 | 0.419 | |||||
| - 295 vs 147 | 0.90 (0.79–1.04) | 0.98 (0.76–1.27) | 0.69 (0.53–0.89) | 0.96 (0.62–1.50) | |||||
| - 589 vs 295 | 0.69 (0.47–1.00) | 0.91 (0.46–1.82) | 0.49 (0.30–0.80) | 0.83 (0.36–1.91) | |||||
| sTREM-1 (pg/ml) | 0.635 | 0.371 | 0.011 | 0.053 | |||||
| - 85 vs 42 | 0.93 (0.67–1.29) | 1.35 (0.71–2.58) | 0.53 (0.34–0.81) | 1.74 (0.67–4.52) | |||||
| - 169 vs 85 | 0.89 (0.71–1.13) | 0.83 (0.54–1.28) | 0.55 (0.36–0.83) | 0.57 (0.26–1.29) | |||||
| Ferritin (ng/ml) | <0.001 | 0.011 | 0.129 | 0.117 | |||||
| - 243 vs 122 | 1.22 (1.08–1.38) | 0.92 (0.72–1.18) | 1.23 (1.02–1.49) | 0.91 (0.68–1.21) | |||||
| - 487 vs 243 | 1.40 (1.10–1.79) | 0.99 (0.68–1.46) | 1.25 (0.89–1.75) | 0.93 (0.54–1.59) | |||||
| CRP (mg/l) | 0.379 | 0.190 | 0.139 | 0.053 | |||||
| - 28 vs 14 | 0.97 (0.89–1.06) | 1.01 (0.83–1.24) | 0.97 (0.86–1.11) | 0.95 (0.71–1.27) | |||||
| - 56 vs 28 | 0.95 (0.78–1.15) | 1.35 (1.01–1.81) | 0.89 (0.69–1.15) | 1.37 (0.88–2.13) |
Odds ratios are estimated at age of 10 and 25 years, represented as children and adults respectively; Poverall is derived from Wald test for the overall association of the biomarker with the endpoint; Pinteraction is from the test for the interaction between the biomarker and age.